Contemporary Management of Dyslipidemia (original) (raw)

• Sidney S, Quesenberry CP Jr, Jaffe MG, et al. Recent trends in cardiovascular mortality in the united states and public health goals. JAMA Cardiology. 2016;1:594–9.
  Article PubMed Google Scholar
• Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular health promotion and disease reduction. Circulation. 2010;121:586–613.
  Article PubMed Google Scholar
• Roger VL, Sidney S, Fairchild AL, et al. Recommendations for Cardiovascular health and disease surveillance for 2030 and beyond: a policy statement from the American Heart Association. Circulation. 2020;141:e104–19.
  Article PubMed Google Scholar
• Pearson TA, Palaniappan LP, Artinian NT, et al. American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 Update. Circulation. 2013;127:1730–53.
  Article PubMed Google Scholar
• Partridge EE, Mayer-Davis EJ, Sacco RL, Balch AJ. Creating a 21st century global health agenda. Circulation. 2011;123:3012–4.
  Article PubMed Google Scholar
• Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation. 2020;141:e139–596.
  PubMed Google Scholar
• Bhatia RT, Gati S, Papadakis M, Sharma S. The impact of COVID-19 on the continuity of cardiovascular care. Eur Heart J. 2021;42:215–7.
  Article CAS PubMed Google Scholar
• Dong C, Rundek T, Wright CB, Anwar Z, Elkind MSV, Sacco RL. Ideal cardiovascular health predicts lower risks of myocardial infarction, stroke, and vascular death across whites, blacks, and hispanics. Circulation. 2012;125:2975–84.
  Article PubMed PubMed Central Google Scholar
• Folsom AR, Yatsuya H, Nettleton JA, et al. Community prevalence of ideal cardiovascular health, by the american heart association definition, and relationship with cardiovascular disease incidence. J Am Coll Cardiol. 2011;57:1690–6.
  Article PubMed PubMed Central Google Scholar
• Toth PP, Granowitz C, Hull M, Anderson A, Philip S. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids Health Dis. 2019;18:175.
  Article CAS PubMed PubMed Central Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–143.
  PubMed Google Scholar
• Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41:111–88.
  Article PubMed Google Scholar
• Stone NJ, Blumenthal RS, Lloyd-Jones D, Grundy SM. Comparing primary prevention recommendations. Circulation. 2020;141:1117–20.
  Article PubMed Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.
  Article CAS PubMed Google Scholar
• Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310:2061–8.
  Article CAS PubMed PubMed Central Google Scholar
• Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406–15.
  Article CAS PubMed PubMed Central Google Scholar
• Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min Y-I, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med. 2018;169:20–9.
  Article PubMed Google Scholar
• Goff DC, Lloyd-Jones DM, Glen B, et al. ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol. 2013;2014(63):2935–59.
  Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation. 2014;129:S1–45.
  Article PubMed Google Scholar
• Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.
  Article PubMed PubMed Central Google Scholar
• SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439–54.
  Article CAS Google Scholar
• Jacobson TA, Ito MK, Maki KC, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015;9:129–69.
  Article PubMed Google Scholar
• Bays HE, Neff D, Tomassini JE, Tershakovec AM. Ezetimibe: cholesterol lowering and beyond. Null. 2008;6:447–70.
  CAS Google Scholar
• Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307:1302–9.
  Article CAS PubMed Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72.
  Article CAS PubMed PubMed Central Google Scholar
• Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016;316:1289–97.
  Article CAS PubMed Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2020;41:407–77.
  Article PubMed Google Scholar
• Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2020;105:3613–82.
  Article Google Scholar
• Gamboa CM, Safford MM, Levitan EB, et al. Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease. Am J Med Sci. 2014;348:108–14.
  Article PubMed PubMed Central Google Scholar
• Berger JS, Ladapo JA. Underuse of prevention and lifestyle counseling in patients with peripheral artery disease. J Am Coll Cardiol. 2017;69:2293–300.
  Article PubMed PubMed Central Google Scholar
• Tran HV, Waring ME, McManus DD, et al. Underuse of effective cardiac medications among women, middle-aged adults, and racial/ethnic minorities with coronary artery disease (from the National Health and Nutrition Examination Survey 2005 to 2014). Am J Cardiol. 2017;120:1223–9.
  Article PubMed Google Scholar
• McClellan M, Brown N, Califf RM, Warner JJ. Call to action: urgent challenges in cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2019;139:e44–54.
  Article PubMed Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42:3227–337.
  Article PubMed Google Scholar
• Karter AJ, Parker MM, Solomon MD, et al. Effect of out-of-pocket cost on medication initiation, adherence, and persistence among patients with type 2 diabetes: the Diabetes Study of Northern California (DISTANCE). Health Serv Res. 2018;53:1227–47.
  Article PubMed Google Scholar
• Navar AM, Taylor B, Mulder H, et al. Association of prior authorization and out-of-pocket costs with patient access to pcsk9 inhibitor therapy. JAMA Cardiology. 2017;2:1217–25.
  Article PubMed PubMed Central Google Scholar
• Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5:378–87.
  Article CAS PubMed PubMed Central Google Scholar
• Sukhova GK, Williams JK, Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol. 2002;22:1452–8.
  Article CAS PubMed Google Scholar
• Schönbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors. Circulation. 2004;109:II–18.
  Article CAS Google Scholar
• Nobuhiro T, Hisashi K, Masatoshi I, et al. simvastatin attenuates plaque inflammation. J Am Coll Cardiol. 2006;48:1825–31.
  Article CAS Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90056 participants in 14 randomised trials of statins. The Lancet. 2005;366:1267–78.
  Article CAS Google Scholar
• Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596–646.
  PubMed PubMed Central Google Scholar
• Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
  Article CAS PubMed Google Scholar
• Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol. 2014;21:464–74.
  Article PubMed Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment Aetiology and Management. Eur Heart J. 2015;36:1012–22.
  Article CAS PubMed PubMed Central Google Scholar
• Howard JP, Wood FA, Finegold JA, et al. Side effect patterns in a crossover trial of statin, placebo, and no treatment. J Am Coll Cardiol. 2021;78:1210–22.
  Article CAS PubMed PubMed Central Google Scholar
• Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597–603.
  Article PubMed PubMed Central Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. The Lancet. 2010;375:735–42.
  Article CAS Google Scholar
• Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.
  Article PubMed PubMed Central Google Scholar
• Waters DD, Ho JE, DeMicco David A, et al. Predictors of new-onset diabetes in patients treated with atorvastatin. J Am Coll Cardiol. 2011;57:1535–45.
  Article CAS PubMed Google Scholar
• Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–64.
  Article CAS PubMed Google Scholar
• Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2019;4:206–13.
  Article PubMed PubMed Central Google Scholar
• Adusumalli S, Westover JE, Jacoby DS, et al. Effect of passive choice and active choice interventions in the electronic health record to cardiologists on statin prescribing: a cluster randomized clinical trial. JAMA Cardiol. 2021;6:40–8.
  Article PubMed Google Scholar
• Rea F, Biffi A, Ronco R, et al. Cardiovascular outcomes and mortality associated with discontinuing statins in older patients receiving polypharmacy. JAMA Netw Open. 2021;4:e2113186–e2113186.
  Article PubMed PubMed Central Google Scholar
• Navar AM, Roe MT, White JA, et al. Medication discontinuation in the IMPROVE-IT trial. Circulation. 2019;12:e005041.
  PubMed Google Scholar
• Peters Sanne AE, Colantonio LD, Zhao H, et al. Sex differences in high-intensity statin use following myocardial infarction in the United States. J Am Coll Cardiol. 2018;71:1729–37.
  Article CAS PubMed Google Scholar
• Gheorghe G, Toth PP, Bungau S, et al. Cardiovascular risk and statin therapy considerations in women. Diagnostics (Basel). 2020;10:483.
  Article CAS Google Scholar
• Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177–86.
  Article CAS PubMed Google Scholar
• Phan BAP, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag. 2012;8:415–27.
  CAS PubMed PubMed Central Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.
  Article CAS PubMed Google Scholar
• Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet. 2011;377:2181–92.
  Article CAS Google Scholar
• Kashani A, Sallam T, Bheemreddy S, Mann DL, Wang Y, Foody JM. Review of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trials. Am J Cardiol. 2008;101:1606–13.
  Article CAS PubMed Google Scholar
• Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75). Circulation. 2019;140:992–1003.
  Article CAS PubMed Google Scholar
• Shapiro MD, Tavori H, Fazio S. PCSK9. Circ Res. 2018;122:1420–38.
  Article CAS PubMed PubMed Central Google Scholar
• Burnett JR, Hooper AJ. PCSK9—a journey to cardiovascular outcomes. N Engl J Med. 2018;379:2161–2.
  Article PubMed Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.
  Article CAS PubMed Google Scholar
• Marston NA, Giugliano RP, Park J-G, et al. Cardiovascular benefit of lowering LDL cholesterol below 40 mg/dl. Circulation. 2021. https://doi.org/10.1161/CIRCULATIONAHA.121.056536 (Accessed November 8, 2021).
  Article PubMed Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.
  Article CAS PubMed Google Scholar
• Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events. J Am Coll Cardiol. 2019;73:387–96.
  Article CAS PubMed Google Scholar
• Koskinas KC, Windecker S, Pedrazzini G, et al. Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS). J Am Coll Cardiol. 2019;74:2452–62.
  Article CAS PubMed Google Scholar
• Giugliano RP, Mach F, Zavitz K, et al. Cognitive function in a randomized trial of evolocumab. N Engl J Med. 2017;377:633–43.
  Article CAS PubMed Google Scholar
• Baris G, François M, Jianping G, et al. Cognition after lowering LDL-cholesterol with evolocumab. J Am Coll Cardiol. 2020;75:2283–93.
  Google Scholar
• Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497–506.
  Article CAS PubMed Google Scholar
• Moriarty PM, Thompson PD, Cannon CP, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9:758–69.
  Article PubMed Google Scholar
• Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. The Lancet. 2014;383:60–8.
  Article CAS Google Scholar
• Stoekenbroek RM, Kallend D, Wijngaard PL, Kastelein JJ. Inclisiran for the treatment of cardiovascular disease: the ORION clinical development program. Future Cardiol. 2018;14:433–42.
  Article CAS PubMed Google Scholar
• Ballantyne CM, Davidson MH, MacDougall DE, et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia. J Am Coll Cardiol. 2013;62:1154–62.
  Article CAS PubMed Google Scholar
• Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom Randomized Clinical Trial. JAMA. 2019;322:1780–8.
  Article CAS PubMed PubMed Central Google Scholar
• Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–32.
  Article CAS PubMed Google Scholar
• Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27:593–603.
  Article PubMed Google Scholar
• Banach M, Duell PB, Gotto AM Jr, et al. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia. JAMA Cardiology. 2020;5:1124–35.
  Article PubMed Google Scholar
• Nicholls S, Lincoff AM, Bays HE, et al. Rationale and design of the CLEAR-outcomes trial: evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance. Am Heart J. 2021;235:104–12.
  Article CAS PubMed Google Scholar
• Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core Evid. 2019;14:19–30.
  Article CAS PubMed PubMed Central Google Scholar
• Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: Current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262–8.
  Article CAS PubMed Google Scholar
• Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. The Lancet. 2015;385:341–50.
  Article CAS Google Scholar
• Blom DJ, Harada-Shiba M, Rubba P, et al. Efficacy and safety of alirocumab in adults with homozygous familial hypercholesterolemia: the ODYSSEY HoFH Trial. J Am Coll Cardiol. 2020;76:131–42.
  Article CAS PubMed Google Scholar
• Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. The Lancet. 2010;375:998–1006.
  Article CAS Google Scholar
• Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia. Circulation. 2012;126:2283–92.
  Article CAS PubMed Google Scholar
• Cuchel M, Meagher EA, du Toit TH, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. The Lancet. 2013;381:40–6.
  Article CAS Google Scholar
• Banerjee P, Chan K-C, Tarabocchia M, et al. Functional analysis of LDLR (Low-Density Lipoprotein Receptor) variants in patient lymphocytes to assess the effect of evinacumab in homozygous familial hypercholesterolemia patients with a spectrum of LDLR activity. Arterioscler Thromb Vasc Biol. 2019;39:2248–60.
  Article CAS PubMed PubMed Central Google Scholar
• Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for homozygous familial hypercholesterolemia. N Engl J Med. 2020;383:711–20.
  Article CAS PubMed Google Scholar
• Rosenson RS, Burgess LJ, Ebenbichler CF, et al. Evinacumab in patients with refractory hypercholesterolemia. N Engl J Med. 2020;383:2307–19.
  Article CAS PubMed Google Scholar
• Thompson GR, Lowenthal R, Myant NB. Plasma exchange in the management of homozygous familial hypercholesterolæmia. The Lancet. 1975;305:1208–11.
  Article Google Scholar
• King MEE, Breslow JL, Lees RS. Plasma-exchange therapy of homozygous familial hypercholesterolemia. N Engl J Med. 1980;302:1457–9.
  Article CAS PubMed Google Scholar
• Græsdal A, Bogsrud MP, Holven KB, et al. Apheresis in homozygous familial hypercholesterolemia: the results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2012;6:331–9.
  Article PubMed Google Scholar
• Wang A, Richhariya A, Gandra SR, et al. Systematic review of low-density lipoprotein cholesterol apheresis for the treatment of familial hypercholesterolemia. J Am Heart Assoc. 2016;5(7):e003294.
  Article PubMed PubMed Central Google Scholar
• Hudgins LC, Kleinman B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia††a list of participating sites other than The Rogosin Institute is provided in the Appendix. Am J Cardiol. 2008;102:1199–204.
  Article CAS PubMed Google Scholar
• Gidding SS, Ann Champagne M, de Ferranti SD, et al. The agenda for familial hypercholesterolemia. Circulation. 2015;132:2167–92.
  Article PubMed Google Scholar
• Schettler V, Neumann C, Peter C, Scientific Board of GLAR for the German Apheresis Working Group, et al. First data from the German Lipoprotein Apheresis Registry (GLAR). Atheroscler Suppl. 2015;18:41–4.
  Article PubMed Google Scholar
• Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler Suppl. 2013;14:67–70.
  Article CAS PubMed Google Scholar
• D’Erasmo L, Gallo A, Cefalù AB, et al. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. Orphanet J Rare Dis. 2021;16:381.
  Article PubMed PubMed Central Google Scholar
• Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 2020;40:1135–47.
  Article CAS PubMed PubMed Central Google Scholar
• Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72:330–43.
  Article PubMed Google Scholar
• Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a metaanalysis of population-based prospective studies. J Cardiovasc Risk. 1996;3:213–9.
  Article CAS PubMed Google Scholar
• The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371:203–12.
  Article CAS Google Scholar
• Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. The Lancet. 2014;384:626–35.
  Article CAS Google Scholar
• Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease. Circ Res. 2016;118:547–63.
  Article CAS PubMed Google Scholar
• Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease. Am J Cardiol. 2016;118:138–45.
  Article CAS PubMed Google Scholar
• Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis. 1988;8:421–8.
  Article CAS PubMed Google Scholar
• Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 2008;51:724–30.
  Article CAS PubMed Google Scholar
• Johansen MØ, Vedel-Krogh S, Nielsen SF, Afzal S, Davey Smith G, Nordestgaard BG. Per-particle triglyceride-rich lipoproteins imply higher myocardial infarction risk than low-density lipoproteins: copenhagen general population study. Arterioscler Thromb Vasc Biol. 2021;41:2063–75.
  Article CAS PubMed Google Scholar
• Sergio R-R, Xavier R, Belén O, et al. Triglycerides and residual atherosclerotic risk. J Am Coll Cardiol. 2021;77:3031–41.
  Google Scholar
• McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep. 2008;10:386–90.
  Article CAS PubMed Google Scholar
• Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. A VOYAGER meta-analysis of the impact of statin therapy on low-density lipoprotein cholesterol and triglyceride levels in patients with hypertriglyceridemia. Am J Cardiol. 2016;117:1444–8.
  Article CAS PubMed Google Scholar
• Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med. 1987;317:1237–45.
  Article CAS PubMed Google Scholar
• Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999;341:410–8.
  Article CAS PubMed Google Scholar
• Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280.
  Article CAS PubMed Google Scholar
• Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol. 2005;95:120–2.
  Article CAS PubMed Google Scholar
• The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet. 2005;366:1849–61.
  Article CAS Google Scholar
• The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563–74.
  Article PubMed Central Google Scholar
• Keech A, Mitchell P, Summanen P, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. The Lancet. 2007;370:1687–97.
  Article CAS Google Scholar
• Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. The Lancet. 2009;373:1780–8.
  Article CAS Google Scholar
• Bruckert E, Labreuche J, Deplanque D, Touboul P-J, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. J Cardiovasc Pharmacol. 2011;57(2):267–72.
  Article CAS PubMed Google Scholar
• Pradhan AD, Paynter NP, Everett BM, et al. Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study. Am Heart J. 2018;206:80–93.
  Article CAS PubMed Google Scholar
• Bang HO, Dyerberg J, Hjørne N. The composition of food consumed by greenland eskimos. Acta Med Scand. 1976;200:69–73.
  Article CAS PubMed Google Scholar
• Burr ML, Gilbert JF, Holliday RM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). The Lancet. 1989;334:757–61.
  Article Google Scholar
• León H, Shibata MC, Sivakumaran S, Dorgan M, Chatterley T, Tsuyuki RT. Effect of fish oil on arrhythmias and mortality: systematic review. BMJ. 2008;337:a2931.
  Article PubMed PubMed Central Google Scholar
• Wang C, Harris WS, Chung M, et al. n−3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review. Am J Clin Nutr. 2006;84:5–17.
  Article CAS PubMed Google Scholar
• Kromhout D, Giltay EJ, Geleijnse JM. n–3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363:2015–26.
  Article CAS PubMed Google Scholar
• Mozaffarian D, Wu JHY. Omega-3 fatty acids and cardiovascular disease. J Am Coll Cardiol. 2011;58:2047–67.
  Article CAS PubMed Google Scholar
• Leaf A, Kang JX, Xiao Y-F, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation. 2003;107:2646–52.
  Article PubMed Google Scholar
• GISSI-Prevenzione, Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. The Lancet. 1999;354:447–55.
  Article Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. The Lancet. 2007;369:1090–8.
  Article CAS Google Scholar
• Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380:11–22.
  Article CAS PubMed Google Scholar
• Mason RP, Eckel RH. Mechanistic insights from REDUCE-IT STRENGTHen the case against triglyceride lowering as a strategy for cardiovascular disease risk reduction. Am J Med. 2021;134:1085–90.
  Article CAS PubMed Google Scholar
• Panigrahy D, Gilligan MM, Serhan CN, Kashfi K. Resolution of inflammation: an organizing principle in biology and medicine. Pharmacol Therap. 2021;227:107879.
  Article CAS Google Scholar
• Nicholls SJ, Lincoff AM, Garcia M, et al. Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial. JAMA. 2020;324:2268–80.
  Article CAS PubMed PubMed Central Google Scholar
• The ASCEND Study Collaborative Group. Effects of n−3 fatty acid supplements in diabetes mellitus. N Engl J Med. 2018;379:1540–50.
  Article Google Scholar
• Nissen SE, Lincoff AM, Wolski K, et al. Association between achieved ω-3 fatty acid levels and major adverse cardiovascular outcomes in patients with high cardiovascular risk: a secondary analysis of the STRENGTH trial. JAMA Cardiol. 2021. https://doi.org/10.1001/jamacardio.2021.1157 (Accessed June 3, 2021).
  Article PubMed PubMed Central Google Scholar
• Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020;41:3925–32.
  Article CAS PubMed PubMed Central Google Scholar
• Orringer CE, Jacobson TA, Maki KC. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk. J Clin Lipidol. 2019;13:860–72.
  Article PubMed Google Scholar
• Whitney E. The air force/Texas coronary atherosclerosis prevention study: implications for preventive cardiology in the general adult US population. Curr Atheroscler Rep. 1999;1:38–43.
  Article CAS PubMed Google Scholar
• Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet. 2003;361:1149–58.
  Article CAS Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. The Lancet. 2004;364:685–96.
  Article CAS Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. The Lancet. 2002;360:7–22.
  Article Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. The Lancet. 2002;360:1623–30.
  Article CAS Google Scholar
• Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–8.
  Article CAS PubMed Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). The Lancet. 1994;344:1383–9.
  Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes phase Z of the A to Z Trial. JAMA. 2004;292:1307–16.
  Article PubMed Google Scholar
• Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med. 1999;341:70–6.
  Article CAS PubMed Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–9.
  Article CAS PubMed Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–45.
  Article CAS PubMed Google Scholar
• The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.
  Article Google Scholar
• Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention a randomized controlled trial. JAMA. 2002;287:3215–22.
  Article CAS PubMed Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–8.
  Article CAS PubMed Google Scholar
• Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.
  Article CAS PubMed Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis a randomized controlled trial. JAMA. 2004;291:1071–80.
  Article CAS PubMed Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.
  Article CAS PubMed Google Scholar